A breakthrough CAR-T cell therapy, Qartemi, has been approved for blood cancer patients in India, offering new hope to those ...

The FDA made strides in R/R T-cell lymphoma and breast cancer. An AI tool aids pathologists and other positive updates in gastric cancer and NSCLC.

Response to humanized defucosylated anti-CCR4 antibody (KW-0761) in a representative patient with acute-type adult T-cell leukemia–lymphoma. The time course of lymphocytes and adult T-cell ...

Suleika is an accomplished journalist, motivational speaker and author who has inspired followers around the world due to her ...

Within a large group of more than 700 patients treated with CAR T cell therapy, researchers found no evidence that the ...

Kids usually don’t get ... of leukemia. Most people live with CLL much longer than with other cancers or other types of leukemia. CLL and ALL begin in the bone marrow, where blood cells are ...

Within a large group of more than 700 patients treated with CAR T cell therapy, researchers found no evidence that the therapy itself caused any type of secondary cancer in the modified T cells, ...

A study of 783 patients treated with CAR T cell therapy found no evidence that the therapy itself caused secondary cancers.

Bristol Myers Squibb today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Breyanzi® (lisocabtagene maraleucel; ...

The EC's decision was based on results from a Phase III trial of Blincyto with multiphase consolidation chemotherapy.

The EC's decision was based on results from a Phase III trial of Blincyto with multiphase consolidation chemotherapy.

AUCATZYL® is their proprietary CD19-directed CAR T cell therapy ... revealed a 76.6% complete remission rate in adult B-cell Acute Lymphoblastic Leukemia (ALL) patients treated with obecabtagene ...